Organoid Modeling of the Tumor Immune Microenvironment

肿瘤免疫微环境的类器官模型

阅读:3
作者:James T Neal,Xingnan Li,Junjie Zhu,Valeria Giangarra,Caitlin L Grzeskowiak,Jihang Ju,Iris H Liu,Shin-Heng Chiou,Ameen A Salahudeen,Amber R Smith,Brian C Deutsch,Lillian Liao,Allison J Zemek,Fan Zhao,Kasper Karlsson,Liora M Schultz,Thomas J Metzner,Lincoln D Nadauld,Yuen-Yi Tseng,Sahar Alkhairy,Coyin Oh,Paula Keskula,Daniel Mendoza-Villanueva,Francisco M De La Vega,Pamela L Kunz,Joseph C Liao,John T Leppert,John B Sunwoo,Chiara Sabatti,Jesse S Boehm,William C Hahn,Grace X Y Zheng,Mark M Davis,Calvin J Kuo

Abstract

In vitro cancer cultures, including three-dimensional organoids, typically contain exclusively neoplastic epithelium but require artificial reconstitution to recapitulate the tumor microenvironment (TME). The co-culture of primary tumor epithelia with endogenous, syngeneic tumor-infiltrating lymphocytes (TILs) as a cohesive unit has been particularly elusive. Here, an air-liquid interface (ALI) method propagated patient-derived organoids (PDOs) from >100 human biopsies or mouse tumors in syngeneic immunocompetent hosts as tumor epithelia with native embedded immune cells (T, B, NK, macrophages). Robust droplet-based, single-cell simultaneous determination of gene expression and immune repertoire indicated that PDO TILs accurately preserved the original tumor T cell receptor (TCR) spectrum. Crucially, human and murine PDOs successfully modeled immune checkpoint blockade (ICB) with anti-PD-1- and/or anti-PD-L1 expanding and activating tumor antigen-specific TILs and eliciting tumor cytotoxicity. Organoid-based propagation of primary tumor epithelium en bloc with endogenous immune stroma should enable immuno-oncology investigations within the TME and facilitate personalized immunotherapy testing.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。